Evidence map›Paper›PMID 42091822›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026

Risk equalization and prevention.

Wynand P M M van de Ven

Abstract read
PubMed Publisher
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Wynand P M M van de VenErasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. vandeven@eshpm.eur.nl.ORCID http://orcid.org/0000-0001-9076-3308

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many countries with a competitive health insurance market have implemented a risk equalization system with health-based risk adjusters. An often-heard argument is that health-based equalization payments create a penalty on prevention and health-improving activities, because an insurer that improves its members' health status by effective prevention and good quality care will receive lower future revenues. Eggleston et al. (Can. J. Economics/Revue Canadienne d'economique. 45(4), 1586-1607, (2012)) and Kanters et al. (Soc. Sci. Med. 76, 150-158, (2013)) conclude that perfect prospective risk equalization entirely removes an insurer's incentives for prevention. The goal of this paper is to refute their conclusion. Based on theoretical counterarguments it can be concluded that in the case of both perfect and imperfect health-based prospective risk equalization, insurers have substantial incentives for prevention and health-improving activities. While an insurer bears the full costs of prevention and health promotion activities and may miss some of the future returns, there is empirical evidence that sophisticated (but not perfect) health-based prospective risk equalization does not, in practice, prevent insurers from (1) voluntarily offering coverage for various forms of prevention, (2) voluntarily providing preventive services, and (3) offering their enrollees good quality care, and - thereby - improving the health status of their enrollees. With concurrent (or retrospective) risk equalization insurers are likely to have less incentives for prevention than with prospective risk equalization.

Indexed as

PreventionRisk equalizationRisk selection

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.